Does Myo-inositol Match Metformin? Moderate Evidence, 6 Studies Reviewed
Across 8 head-to-head trials in 1,088 women with PCOS, myo-inositol and metformin did not differ on BMI (SMD 0.16), fasting insulin (SMD 0.00), fasting glucose (SMD 0.11), HOMA index (SMD 0.09) or LH to FSH ratio (SMD 0.20) (PMID 37148410). That sounds like a draw, and on the metabolic numbers it is. But a draw in a trial with no placebo arm tells you the two agents moved together, not that either one moved anything, and the six studies we reviewed for this comparison differ on which agent wins on cycles, which wins on insulin, and which is easier to tolerate. The full grade for every myo-inositol claim is on the myo-inositol review hub.
Presented By Our Partners
Where the two agents tie
The 2023 meta-analysis of 8 trials is the cleanest comparison in the set. Its confidence intervals all straddle zero: BMI SMD 0.16 (95% CI -0.11 to 0.43), fasting insulin SMD 0.00 (95% CI -0.26 to 0.27), fasting glucose SMD 0.11 (95% CI -0.31 to 0.53), HOMA SMD 0.09 (95% CI -0.20 to 0.39) (PMID 37148410). An earlier 9-study review of 638 women reported larger percentage reductions with myo-inositol in LH (12.55% versus 7.97%) and testosterone (44.38% versus 8.48%), yet its authors concluded that scarce research and high heterogeneity meant no difference could be established, and the abstract repeats the same LH figure for both groups in one place, which suggests transcription errors (PMID 33877679).
| Comparison | Result | Design and n | Source |
|---|---|---|---|
| Myo-inositol versus metformin, metabolic markers | No difference on BMI, insulin, glucose, HOMA, LH/FSH | 8 trials, 1,088 women | PMID 37148410 |
| Myo-inositol versus metformin, hormones | Larger percentage drops in LH and testosterone with myo-inositol, but no difference established | 9 studies, 638 women | PMID 33877679 |
| Metformin plus inositol versus metformin alone | Regular cycles RR 1.56 (95% CI 1.01 to 2.41); hirsutism score -0.97; no change in BMI, glucose or HOMA-IR | 6 trials, 388 women | PMID 39331347 |
| 40:1 combination versus metformin, menstrual frequency | OR 14.70 (95% CI 2.31 to 93.58); HOMA-IR -0.72 to -0.89 versus metformin | 22 trials, 1,079 women, network meta-analysis | PMID 34407851 |
| Four-arm trial, 12 weeks | Cycle regularization 64.6% inositol, 39.6% metformin, 72.9% diet, 85.4% all three | 192 women aged 18 to 35 | PMID 42517336 |
| 40:1 combination versus metformin, 12 weeks | Both improved HOMA-IR, SHBG, cycles and quality of life; metformin slightly better on insulin | 60 women | PMID 39847053 |
Where they diverge
Cycle regularity is where inositol looks strongest. In the 2026 four-arm trial, 64.6% of women on myo-inositol 2 g plus D-chiro-inositol 50 mg twice daily regularized their cycles at 12 weeks versus 39.6% on metformin, though a 1,200 to 1,500 kcal diet alone did better than either at 72.9%, and combining all three reached 85.4% (PMID 42517336). A 22-trial network meta-analysis gave the 40:1 combination an odds ratio of 14.70 over metformin for menstrual frequency, with a confidence interval from 2.31 to 93.58 that tells you how few trials sit behind it (PMID 34407851). Insulin sensitivity tilts the other way: in the 60-woman trial, metformin was slightly better on HOMA-IR and endocrine markers over 12 weeks (PMID 39847053), and when inositol was added on top of metformin, fasting glucose and HOMA-IR did not change at all (PMID 39331347).
Featured Partner
Invest in the Infrastructure Behind Modern Medicine
As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.
Learn More →
The swap question
The question most readers are really asking is whether a supplement can stand in for a prescription. The honest answer from these six studies is that the two have performed similarly on surrogate markers in women with PCOS over 3 to 6 months, that inositol has an edge on cycle regularity and metformin a slight edge on insulin, and that none of these trials included a placebo group, so neither agent’s absolute effect can be read from them. Metformin has decades of outcome data in type 2 diabetes that inositol does not, and none of the studies we reviewed tested inositol against metformin in anyone without PCOS.
What we do not know
Trial durations are often unstated in the abstracts, heterogeneity was moderate for BMI, glucose and LH to FSH ratio (PMID 37148410), and the inositol-arm changes in HOMA-IR and BMI from the four-arm trial were not reported in its abstract (PMID 42517336). Whether myo-inositol alone matches the 40:1 combination, and whether any of this holds past 6 months, is not answered by this set.
Doses used in studies
These are doses reported by the named sources, not recommendations.
| Source | Dose as reported | Context |
|---|---|---|
| PMID 42517336 | Myo-inositol 2 g plus D-chiro-inositol 50 mg twice daily; metformin 1,500 to 2,000 mg per day in the comparator arm | 192 women with PCOS, 12 weeks |
| PMID 39847053 | 40:1 myo-inositol to D-chiro-inositol for 12 weeks; absolute dose not stated | 60 women with PCOS versus metformin |
| PMID 33877679 | Myo-inositol, dose not stated in abstract | 9 studies, 638 women |
Back to the myo-inositol review hub. For a parallel comparison of another supplement against the same drug, see does berberine work like metformin.
Similar Posts
Emotiv Insight 2.0 Review: 5-Channel EEG, Price, and Real Limits
The Emotiv Insight 2.0 is a 5-channel wireless EEG headset for BCI prototyping and learning. Real raw data; unvalidated focus scores; not a medical device.
Keyto Breath Sensor: Budget Breath Acetone Tracking for Keto Dieters
A pocket sensor that reads fat metabolism through your breath, promising to replace urine strips and finger pricks for anyone following a ketogenic diet. Presented By Our Partners In healthy…
Five Years of Proof: The Personalized mRNA Cancer Vaccine That Halved Melanoma Recurrence
Five-year data from the KEYNOTE-942 trial, presented at ASCO 2026, show that intismeran autogene plus Keytruda sustains a 49% reduction in melanoma recurrence risk and drives overall survival to 92.2%…
Medical AI Has a New Test: Did the Patient Get Better Care?
A new Nature Medicine collection makes the case that medical AI should be judged by what happens after the prediction: contact, follow-up, completed care, outcomes, and harms.
What Is HealthBench? How OpenAI’s Medical AI Benchmark Tests Models Against Doctors
HealthBench is becoming one of medical AI’s most influential scoreboards. Here is how physicians built it, what its model-versus-doctor results mean, and why a high score is not the same…
The Cash-Pay GLP-1 Trap: What to Check Before the Price Looks Cheap
A source-backed framework for comparing cash-pay GLP-1 offers: medication identity, total cost, clinical accountability, pharmacy verification, dose changes, cancellation, and continuity.
